Cadrenal Therapeutics Q3 2026 Earnings Date & Estimates

Cadrenal Therapeutics (NASDAQ:CVKD) (NASDAQ: CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients who require long-term anticoagulation. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant designed for individuals with implanted mechanical heart valves and other mechanical circulatory support devices.

Tecarfarin is a vitamin K antagonist intended to address challenges associated with existing anticoagulant therapy, including drug interactions and changes in a patient’s metabolism. Cadrenal has evaluated the candidate in clinical studies and has pursued its development for patients with mechanical heart valves and left ventricular assist devices, populations that may require lifelong anticoagulation to reduce the risk of blood clots.

Cadrenal Therapeutics is based in Ponte Vedra Beach, Florida, and was founded by Quang X. Pham, who serves as the company’s chief executive officer. The company’s development activities are primarily focused on advancing tecarfarin through clinical and regulatory evaluation in the United States.